Navigation Links
Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Date:12/19/2011

PALO ALTO, Calif., Dec. 19, 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) announced today that it will report results for the first quarter of fiscal year 2012 following the close of regular trading on Wednesday, January 25, 2012.  The news release will be followed by a teleconference available to all interested parties at 2:00 p.m. PT.  The news release and a link to the conference call webcast will be available on the company website at: www.varian.com/investor.  To access the teleconference call and replay:Teleconference:

Access from within the U.S. by dialing 1-866-700-0161, and from outside the U.S. by dialing 1-617-213-8832, and entering code 37675518. 

 Replay:

 

Access from within the U.S. by dialing 1-888-286-8010 and from outside the U.S. by dialing 1-617-801-6888, and entering code 39547714. The teleconference will be rebroadcast until 8:00 p.m. ET, Friday, January 27, 2012. 

 Webcast: 

Visit the company website at: www.varian.com/investor and click on the "Quarterly Conference Call" icon. Web conferences will be archived on the company website for a year.  For automatic "e-mail alerts" regarding Varian news and events, investors can subscribe on the company website: http://varian.investorroom.com/index.php?s=58.
For additional information contact Anne Rambo at 650-424-5834 or anne.rambo@varian.com

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The co
'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
2. deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis
3. deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels
4. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
5. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
6. OVA1 Blood Test Detects Ovarian Cancer More Accurately Than Medically Accepted CA 125 Method for Evaluating Women with Ovarian Mass
7. Prostate cancer risk variant found to be in a functional DNA sequence linked with disease
8. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
9. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
10. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
11. Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains to an ... within a body lumen (open space). Known as ... cost, single-use disposable illumination and camera module (housing). ... and the patent approval was received on January 6, ... the lighting and magnification of the endoscope for different ...
(Date:5/21/2015)... Ontario (PRWEB) May 21, 2015 ... into an exclusive North American distribution agreement with ... testing system. , With more than 160 years ... products and services for laboratory and production facilities, ... operational excellence and differentiated services to enable science. ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) ... Therapy Market Outlook 2020 " report to their ... and regenerative medicine is expected to have huge marketing ... help in the growth of deregulated organs. Several therapeutic ... unable to form new tissue or sometimes organ transplant ...
(Date:5/20/2015)... 20, 2015  Marc Tessier-Lavigne, president of The ... $100 million from The Marie-Josée and Henry R. ... building that will be the centerpiece of the ... Henry R. Kravis Research Building, two stories high, ... approximately three city blocks following the shoreline of ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4
... WILL FOCUS ON COLLECTION, PROCESSING AND STORAGE OF EQUINE ... BONE MARROW AND PLACENTAL TISSUE STEM CELLS, RANCHO ... ), a leading supplier of innovative products and,services that ... its,wholly-owned subsidiary, Vantus, Inc., has signed a formal agreement ...
... Feb. 27 Ocera Therapeutics, a,biopharmaceutical company focused ... to treat a broad range of,gastrointestinal and liver ... joined the company as Chief Medical Officer. Prior ... Chief Medical Officer and Vice,President of Clinical Affairs ...
... Ltd, a specialty,biopharmaceutical company focused on controlling immune ... phase II clinical study with its,anti-allergy technology, ToleroMune. ... cat-dander allergy, and aims to complete the trial ... on the results of a previous double-blind,placebo-controlled phase ...
Cached Biology Technology:ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 2ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 3ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 4ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health 5M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer 2Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology 2
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... a good thing better? A gene known as LIS1 is ... developing brain. When an LIS1 gene is missing, brains fail ... brain, are born severely mentally retarded. But new research by ... recently appeared in Nature Genetics, shows that having ...
... newly described fossil whales--a pregnant female and a male ... and provide new insights into how whales made the ... fossils, discovered in Pakistan in 2000 and 2004, are ... the online journal PLoS. "This stunning ...
... Albert Einstein College of Medicine of Yeshiva University have discovered ... causes disease. The study, published in the ... ( PNAS ), may help scientists develop new therapies or ... fungal infections occur most commonly in those with compromised immune ...
Cached Biology News:Weizmann Institute scientists show extra copies of a gene carry extra risk 2Early whales gave birth on land 2Scientists discover how deadly fungus protects itself 2
... jetSI-ENDO-FluoR is a tetramethylrhodamine-conjugated jetSI-ENDO ... at 580 nm), the powerful ... are used to determine the ... intracellular delivery and trafficking of ...
... Bruker Daltonics and Bruker BioSpins ... for metabolism studies, and analysis of ... ESI-TOF system, an optional Avance NMR ... acquisition, evaluation and statistical analysis for ...
... PreferenceIncludes all features of Tracker, plus software to ... area, and provide a food reward.The Spatial Behavior ... around a video camera, frame grabber, and feature ... at once and up to 6 moving animals. ...
... Tracker w/ OutputCumulates a score of movement ... except that it.can track up to 6 subjects ... can be triggered. Can outpt a sync ... EEG. Can use animal location and timing ...
Biology Products: